Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
23andMe Holding Co. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "23andMe Reports FY2024 First Quarter Financial Results Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., August 8, 2023"
06/09/2023 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
05/25/2023 8-K Quarterly results
Docs: "23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter and full year of fiscal year 2023 , which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired ..."
04/17/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
02/08/2023 8-K Quarterly results
02/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement by and between 23andMe Holding Co. and Cowen and Company, LLC, (incorporated by reference to Exhibit 1.2 to 23andMe Holding Co.’s Registration Statement on Form S-3 filed on February 6, 2023)"
12/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Second Amended and Restated Bylaws of 23andMe Holding Co",
"23andMe Holding Co. Change in Control Separation Plan"
11/09/2022 8-K Investor presentation
Docs: "2 3 4 1 JAMA,"
11/07/2022 8-K Quarterly results
Docs: "23andMe Reports FY2023 Second Quarter Financial Results Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance South San Francisco, Calif., November 7, 2022 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the second quarter of its fiscal year 2023 , which ended September 30, 2022. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports..."
11/04/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
08/31/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/19/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
04/13/2022 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events  Interactive Data
02/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "12.2M1 1.6M 825,000 500,000 366,000 219,000 500,000 REGENERON ALL OF US MILLION VETERAN PROGRAM FINNGEN UK BIOBANK DECODE GENETICS GENOMICS ENGLAND"
02/10/2022 8-K Quarterly results
Docs: "23andMe Reports FY2022 Third Quarter Financial Results Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., February 10, 2022 -- 23andMe Holding Co. , a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter of its fiscal year 2022 , which ended December 31, 2021. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company FDA authorized to provide, without physician involvemen..."
01/18/2022 8-K Investor presentation
Docs: "11.9M1 1M 825,000 500,000 366,000 219,000 500,000 REGENERON ALL OF US MILLION VETERAN PROGRAM FINNGEN UK BIOBANK DECODE GENETICS GENOMICS ENGLAND",
"23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody collaboration program targeting CD96 into development Company will discuss at its R&D Day event today at 8:00 a.m. Pacific Time SUNNYVALE, CA - January 18, 2022 - 23andMe Holding Co. , a leading consumer genetics and therapeutics company, today provided an update on its collaboration with GlaxoSmithKline plc . GSK has elected to exercise its option to extend the exclusive target discovery period of the ongoing collaboration with 23andMe for ..."
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation SUNNYVALE, CA - January 10, 2022 - 23andMe Holding Co. , a leading consumer genetics and research company, today received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company’s third cancer risk report clearance, following the FDA’s prior authorization for 23andMe’s BRCA1/BRCA2 Genetic Health Risk report and its clearance for MUTYH-Associated Polyposis , a hereditary colorectal cancer syndrome. These two reports along with the new Hereditary Prostat..."
01/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors 23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022"
12/28/2021 8-K Quarterly results
11/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "23andMe Announces Redemption of All Outstanding Warrants",
"Notice of Redemption"
11/10/2021 8-K Quarterly results
Docs: "23andMe Reports FY2022 Second Quarter Financial Results"
11/09/2021 8-K Appointed a new director
Docs: "23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors"
11/02/2021 8-K Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"23andMe Announces the Closing of its Acquisition of Lemonaid Health"
10/22/2021 8-K Quarterly results
09/10/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"23andMe Reports FY2022 First Quarter Financial Results"
06/21/2021 8-K Director compensation was amended/approved
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Certificate of Corporate Domestication of VG Acquisition Corp",
"Amended and Restated Registration Rights Agreement, by and among 23andMe Holding Co., VG Acquisition Sponsor LLC, and certain other initial stockholders",
"Includes 98,702,638 shares of New 23andMe Class B Common Stock that are convertible into New 23andMe Class A stock on a share-for-share basis",
"Includes 98,702,638 shares of New 23andMe Class B Common Stock that are convertible into New 23andMe Class A stock on a share-for-share basis",
"The beneficial ownership of New 23andMe as of the Closing Date is based on (A) 92,655,484 shares of New 23andMe Class A Common Stock outstanding as of such date and (B) 313,759,355 shares of New 23andMe Class B Common Stock outstanding as of such date",
"Audited Consolidated Financial Statements and Related Notes of 23andMe Holding Co. as of March 31, 2021 and 2020 and for the Fiscal Years Ended March 31, 2021, 2020 and 2019",
"Unaudited Pro Forma Condensed Combined Financial Information of 23andMe Holding Co. at March 31, 2021"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy